Peer Review History

Original SubmissionAugust 24, 2020
Decision Letter - Giordano Madeddu, Editor

PONE-D-20-26498

Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: a Retrospective, Observational Cohort Study

PLOS ONE

Dear Dr. Costa Monteiro,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 17 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Giordano Madeddu

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include the date(s) on which you accessed the databases or records to obtain the data used in your study.

3. Please define current, former, and never smoker statuses.

4. Thank you for stating the following in the Competing Interests section:

"I have read the journal's policy and the authors of this manuscript have the following competing interests: SYC consults for PureTech on their deupirfenidone in COVID study. "

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The goal of this study was to evaluate respiratory failure in COVID-19 and explore factors associated

with risk of invasive mechanical ventilation (IMV). A retrospective, observational cohort study of 112 inpatient adults diagnosed with COVID-19 was carried out. Data were manually extracted from electronic

medical records. Multivariable and Univariable regression were used to evaluate association between

baseline characteristics, initial serum markers and the outcome of IMV. It was determined that obesity, smoking history, and elevated inflammatory markers were associated with increased need for IMV in patients with COVID-19. These findings are of utmost importance given the current scenario.

Reviewer #2: In this study (PONE-D-20-26498), Monteiro and colleagues described a small sample (28), who needed endotracheal intubation and invasive mechanical ventilation, among 112 COVID-19 included in the analysis. The idea is interesting the paper is well written, however I have some considerations to explain. First of all they described that 28 patients out 47 admitted to the ICU were intubated, but they did not describe the criteria of intubation.

Could you describe the intubation criteria that you used, please?

Moreover they did not describe any severity score, i.e. APACHE II, SAPS II.

Could you add a severity score to understand better the severity of your population admitted to ICU, since your mortality rate was very low compared to other ICU?

Regarding mechanical ventilation, they described a setting of median PEEP level of 10-12 cmH2O in severe ARDS and P/F rati < 150, but they did not describe any data on plateau pressure, driving pressure or compliance of the respiratory system. Therefore how did you decide to set PEEP level? Could you you described better respiratory mechanics (plateau pressure, driving pressure, PEEPi, compliance of the respiratory system)? Which criteria did you consider to decide for prone positioning? Could you report the duration of mechanical ventilation?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Daniela Pasero

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

This Document has also been uploaded for ease of viewing.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

We have revised the manuscript to comply to the above guidelines.

2. Please include the date(s) on which you accessed the databases or records to obtain the data used in your study.

We have added the following sentence to the manuscript methods section:

“This is a retrospective observational cohort study conducted from March 12 2020 and April 16 2020 approved by the UCLA (University of California, Los Angeles) institutional review board with waiver of informed consent. We evaluated the first 113 unique admissions to our healthcare system. We originally accessed patient charts between March 12 and June 16th 2020. We returned to the charts in October 2020 to extract elements requested during the review process.”

3. Please define current, former, and never smoker statuses.

We have added these definitions to the methods section:

“We extracted smoking status from the admission note. Patients were interviewed about smoking history on admission. Never smokers, prior smokers and current smokers were self-identified as such by the patients during the interview. Those patients who self-identified as prior smokers were then asked when they last smoked and number of packs a day. Those who identified as current smokers were asked the number of packs smoked a day. Patients who smoked less than a pack-year were considered never smokers.”

4. Thank you for stating the following in the Competing Interests section: "I have read the journal's policy and the authors of this manuscript have the following competing interests: SYC consults for PureTech on their deupirfenidone in COVID study. "

We have added the following to our cover letter:

“I have read the journal's policy and the authors of this manuscript have the following competing interests: SYC consults for PureTech on their deupirfenidone in COVID study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.”

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

We have since uploaded the data used in the manuscript in the public repository https://datadryad.org/stash. The DOI is https://doi.org/10.5068/D1QX18. It will be made public once the manuscript is accepted. In the meantime you may access this at https://datadryad.org/stash/share/SJtUG1lXSBD9KlQcQapB1x1g7yJAvhFxqcInaILQy1w

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Thank you, we have completed this.

In Response to reviewers' comments:

Reviewer #1: The goal of this study was to evaluate respiratory failure in COVID-19 and explore factors associated with risk of invasive mechanical ventilation (IMV). A retrospective, observational cohort study of 112 inpatient adults diagnosed with COVID-19 was carried out. Data were manually extracted from electronic medical records. Multivariable and Univariable regression were used to evaluate association between baseline characteristics, initial serum markers and the outcome of IMV. It was determined that obesity, smoking history, and elevated inflammatory markers were associated with increased need for IMV in patients with COVID-19. These findings are of utmost importance given the current scenario.

We appreciate your support of our manuscript.

Reviewer #2: In this study (PONE-D-20-26498), Monteiro and colleagues described a small sample (28), who needed endotracheal intubation and invasive mechanical ventilation, among 112 COVID-19 included in the analysis. The idea is interesting the paper is well written, however I have some considerations to explain. First of all they described that 28 patients out 47 admitted to the ICU were intubated, but they did not describe the criteria of intubation. Could you describe the intubation criteria that you used, please?

Thank you for pointing this out. In the methods we have now added the following statement:

“Guidelines recommended intubation for patients who had PCR confirmed COVID-19 and who demonstrated rapid escalation of oxygen requirements. It was at the discretion of the clinician to decide whether a patient would tolerate a trial of non-invasive oxygen delivery via non-rebreather mask or high flow nasal canula (HFNC). If the clinician decided that trial of these non-invasive therapies would place the patient and/or staff at greater risk, the patient would proceed to intubation.”

- Moreover they did not describe any severity score, i.e. APACHE II, SAPS II. Could you add a severity score to understand better the severity of your population admitted to ICU, since your mortality rate was very low compared to other ICU?

We appreciate the suggestion. We re-evaluated the COVID literature and found a recent study on COVID-19 patients from Wuhan which reported that APACHE II outperformed SOFA and CURB-65 as a predictor of mortality in this population (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217128/). As such, we chose to calculate APACHE II for the patients in our cohort who were admitted to the ICU. We have added the following to the results sections:

“Out of the 47 ICU admissions, the median APACHE II score on arrival to the ICU was 12 (IQR 7-16, mean 12.7, SD 7.11).”

In comparison, the cohort from Wuhan, China had a mean APACHE score of 15 +- SD 7.7 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217128/). Considering the population size, standard deviation and means of these two populations, a two tailed t-test revealed that the APACHE scores in these two populations were not significantly different.

- Regarding mechanical ventilation, they described a setting of median PEEP level of 10-12 cmH2O in severe ARDS and P/F ratio < 150, but they did not describe any data on plateau pressure, driving pressure or compliance of the respiratory system. Therefore how did you decide to set PEEP level? Could you describe better respiratory mechanics (plateau pressure, driving pressure, PEEP, compliance of the respiratory system)? Which criteria did you consider to decide for prone positioning? Could you report the duration of mechanical ventilation?

As stated in our methods, we recommended PEEP titration per ARDS network PEEP tables and prone positioning when P/F <150, as recommended by the PROSEVA trial: “…early consideration of prone ventilation for patients with P/F ratios < 150” and “Titration of positive end-expiratory pressure (PEEP) was recommended to reflect ARDS network PEEP tables”.

We have also added that we recommended PPlat to stay under 30 cm H2O.

We have since included the static compliance of patients who were intubated, as measured as part of our respiratory therapy routine care. We have added the following to our manuscript:

“ For the intubated patients, compliance on day of intubation (day 1) had a median value of 34.1 ml/cm H2O (IQR = 24.6-41.8, mean 34.0, SD 10.4), for day 3 the median was 30.3 (IQR 23.9-40.1, mean 32.7, SD 10.4), for day 5 the median was 34.6 (IQR 26.9-39.9, mean 35.4, SD 12.4) and for day 7 the median was 34.7 (IQR 30.7-52.5, mean 38.8, SD 11.7).”

Interestingly, the static compliance measured in these patients were most similar to the non COVID ARDS arm reported in the Grasselli study (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2820%2930370-2/fulltext), in which they reported a median compliance of 32 ml/cm H2O (IQR 25-43), and lower than the median of 41 reported for the COVID-19 arm of the same study.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Giordano Madeddu, Editor

Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: a Retrospective, Observational Cohort Study

PONE-D-20-26498R1

Dear Dr. Costa Monteiro,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Giordano Madeddu

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: Congratulations,

the authors addressed all comments, and the manuscript is now suitable for acceptance.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Shama Ahmad

Reviewer #2: Yes: Daniela Pasero

Formally Accepted
Acceptance Letter - Giordano Madeddu, Editor

PONE-D-20-26498R1

Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort Study

Dear Dr. Monteiro:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Giordano Madeddu

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .